Preoperative methylprednisolone does not reduce loss of knee-extension strength after total knee arthroplasty: A randomized, double-blind, placebo-controlled trial of 61 patients

Research output: Contribution to journalJournal articleResearchpeer-review

Standard

Preoperative methylprednisolone does not reduce loss of knee-extension strength after total knee arthroplasty : A randomized, double-blind, placebo-controlled trial of 61 patients. / Lindberg-Larsen, Viktoria; Bandholm, Thomas Q; Zilmer, Camilla K; Bagger, Jens; Hornsleth, Mette; Kehlet, Henrik.

In: Acta Orthopaedica, Vol. 88, No. 5, 2017, p. 543-549.

Research output: Contribution to journalJournal articleResearchpeer-review

Harvard

Lindberg-Larsen, V, Bandholm, TQ, Zilmer, CK, Bagger, J, Hornsleth, M & Kehlet, H 2017, 'Preoperative methylprednisolone does not reduce loss of knee-extension strength after total knee arthroplasty: A randomized, double-blind, placebo-controlled trial of 61 patients', Acta Orthopaedica, vol. 88, no. 5, pp. 543-549. https://doi.org/10.1080/17453674.2017.1345236

APA

Lindberg-Larsen, V., Bandholm, T. Q., Zilmer, C. K., Bagger, J., Hornsleth, M., & Kehlet, H. (2017). Preoperative methylprednisolone does not reduce loss of knee-extension strength after total knee arthroplasty: A randomized, double-blind, placebo-controlled trial of 61 patients. Acta Orthopaedica, 88(5), 543-549. https://doi.org/10.1080/17453674.2017.1345236

Vancouver

Lindberg-Larsen V, Bandholm TQ, Zilmer CK, Bagger J, Hornsleth M, Kehlet H. Preoperative methylprednisolone does not reduce loss of knee-extension strength after total knee arthroplasty: A randomized, double-blind, placebo-controlled trial of 61 patients. Acta Orthopaedica. 2017;88(5):543-549. https://doi.org/10.1080/17453674.2017.1345236

Author

Lindberg-Larsen, Viktoria ; Bandholm, Thomas Q ; Zilmer, Camilla K ; Bagger, Jens ; Hornsleth, Mette ; Kehlet, Henrik. / Preoperative methylprednisolone does not reduce loss of knee-extension strength after total knee arthroplasty : A randomized, double-blind, placebo-controlled trial of 61 patients. In: Acta Orthopaedica. 2017 ; Vol. 88, No. 5. pp. 543-549.

Bibtex

@article{47050312d5d04b10bba52f658c285961,
title = "Preoperative methylprednisolone does not reduce loss of knee-extension strength after total knee arthroplasty: A randomized, double-blind, placebo-controlled trial of 61 patients",
abstract = "Background and purpose - Patients undergoing total knee arthroplasty (TKA) face challenges related to postoperative reduction in knee-extension strength. We evaluated whether inhibition of the inflammatory response by a single preoperative dose of methylprednisolone (MP) reduces the pronounced loss of knee-extension strength at discharge after fast-track TKA. Patients and methods - 70 patients undergoing elective unilateral TKA were randomized (1:1) to preoperative intravenous (IV) MP 125 mg (group MP) or isotonic saline IV (group C). All procedures were performed under spinal anesthesia without tourniquet, and with a standardized multimodal analgesic regime. The primary outcome was change in knee-extension strength from baseline to 48 hours postoperatively. Secondary outcomes were knee joint circumference, functional performance using the Timed Up and Go (TUG) test, pain during the aforementioned tests, rescue analgesic requirements, and plasma C-reactive protein (CRP) changes. Results - 61 patients completed the follow-up. The loss in quadriceps muscle strength was similar between groups; group MP 1.04 (0.22-1.91) Nm/kg (-89%) vs. group C 1.02 (0.22-1.57) Nm/kg (-88%). Also between-group differences were similar for knee circumference, TUG test, and pain scores. MP reduced the inflammatory response (CRP) at 24 hours postoperatively; group MP 33 (IQR 21-50) mg/L vs. group C 72 (IQR 58-92) mg/L (p < 0.001), and 48 hours postoperatively; group MP 83 (IQR 56-125) mg/L vs. group C 192 (IQR 147-265) mg/L (p < 0.001), respectively. Interpretation - Preoperative systemic administration of MP 125 mg did not reduce the pronounced loss of knee-extension strength or other functional outcomes at discharge after fast-track TKA despite a reduced systemic inflammatory response.",
keywords = "Aged, Aged, 80 and over, Anti-Inflammatory Agents, Arthroplasty, Replacement, Knee, Double-Blind Method, Female, Humans, Injections, Intravenous, Male, Methylprednisolone, Middle Aged, Muscle Strength, Preoperative Care, Range of Motion, Articular, Journal Article, Randomized Controlled Trial",
author = "Viktoria Lindberg-Larsen and Bandholm, {Thomas Q} and Zilmer, {Camilla K} and Jens Bagger and Mette Hornsleth and Henrik Kehlet",
year = "2017",
doi = "10.1080/17453674.2017.1345236",
language = "English",
volume = "88",
pages = "543--549",
journal = "Acta Orthopaedica",
issn = "1745-3674",
publisher = "Taylor & Francis",
number = "5",

}

RIS

TY - JOUR

T1 - Preoperative methylprednisolone does not reduce loss of knee-extension strength after total knee arthroplasty

T2 - A randomized, double-blind, placebo-controlled trial of 61 patients

AU - Lindberg-Larsen, Viktoria

AU - Bandholm, Thomas Q

AU - Zilmer, Camilla K

AU - Bagger, Jens

AU - Hornsleth, Mette

AU - Kehlet, Henrik

PY - 2017

Y1 - 2017

N2 - Background and purpose - Patients undergoing total knee arthroplasty (TKA) face challenges related to postoperative reduction in knee-extension strength. We evaluated whether inhibition of the inflammatory response by a single preoperative dose of methylprednisolone (MP) reduces the pronounced loss of knee-extension strength at discharge after fast-track TKA. Patients and methods - 70 patients undergoing elective unilateral TKA were randomized (1:1) to preoperative intravenous (IV) MP 125 mg (group MP) or isotonic saline IV (group C). All procedures were performed under spinal anesthesia without tourniquet, and with a standardized multimodal analgesic regime. The primary outcome was change in knee-extension strength from baseline to 48 hours postoperatively. Secondary outcomes were knee joint circumference, functional performance using the Timed Up and Go (TUG) test, pain during the aforementioned tests, rescue analgesic requirements, and plasma C-reactive protein (CRP) changes. Results - 61 patients completed the follow-up. The loss in quadriceps muscle strength was similar between groups; group MP 1.04 (0.22-1.91) Nm/kg (-89%) vs. group C 1.02 (0.22-1.57) Nm/kg (-88%). Also between-group differences were similar for knee circumference, TUG test, and pain scores. MP reduced the inflammatory response (CRP) at 24 hours postoperatively; group MP 33 (IQR 21-50) mg/L vs. group C 72 (IQR 58-92) mg/L (p < 0.001), and 48 hours postoperatively; group MP 83 (IQR 56-125) mg/L vs. group C 192 (IQR 147-265) mg/L (p < 0.001), respectively. Interpretation - Preoperative systemic administration of MP 125 mg did not reduce the pronounced loss of knee-extension strength or other functional outcomes at discharge after fast-track TKA despite a reduced systemic inflammatory response.

AB - Background and purpose - Patients undergoing total knee arthroplasty (TKA) face challenges related to postoperative reduction in knee-extension strength. We evaluated whether inhibition of the inflammatory response by a single preoperative dose of methylprednisolone (MP) reduces the pronounced loss of knee-extension strength at discharge after fast-track TKA. Patients and methods - 70 patients undergoing elective unilateral TKA were randomized (1:1) to preoperative intravenous (IV) MP 125 mg (group MP) or isotonic saline IV (group C). All procedures were performed under spinal anesthesia without tourniquet, and with a standardized multimodal analgesic regime. The primary outcome was change in knee-extension strength from baseline to 48 hours postoperatively. Secondary outcomes were knee joint circumference, functional performance using the Timed Up and Go (TUG) test, pain during the aforementioned tests, rescue analgesic requirements, and plasma C-reactive protein (CRP) changes. Results - 61 patients completed the follow-up. The loss in quadriceps muscle strength was similar between groups; group MP 1.04 (0.22-1.91) Nm/kg (-89%) vs. group C 1.02 (0.22-1.57) Nm/kg (-88%). Also between-group differences were similar for knee circumference, TUG test, and pain scores. MP reduced the inflammatory response (CRP) at 24 hours postoperatively; group MP 33 (IQR 21-50) mg/L vs. group C 72 (IQR 58-92) mg/L (p < 0.001), and 48 hours postoperatively; group MP 83 (IQR 56-125) mg/L vs. group C 192 (IQR 147-265) mg/L (p < 0.001), respectively. Interpretation - Preoperative systemic administration of MP 125 mg did not reduce the pronounced loss of knee-extension strength or other functional outcomes at discharge after fast-track TKA despite a reduced systemic inflammatory response.

KW - Aged

KW - Aged, 80 and over

KW - Anti-Inflammatory Agents

KW - Arthroplasty, Replacement, Knee

KW - Double-Blind Method

KW - Female

KW - Humans

KW - Injections, Intravenous

KW - Male

KW - Methylprednisolone

KW - Middle Aged

KW - Muscle Strength

KW - Preoperative Care

KW - Range of Motion, Articular

KW - Journal Article

KW - Randomized Controlled Trial

U2 - 10.1080/17453674.2017.1345236

DO - 10.1080/17453674.2017.1345236

M3 - Journal article

C2 - 28657396

VL - 88

SP - 543

EP - 549

JO - Acta Orthopaedica

JF - Acta Orthopaedica

SN - 1745-3674

IS - 5

ER -

ID: 184879232